Freeline Therapeutics Holdings plc
CIK 0001810031
Revenue (TTM)
—
Q3 Sep 2023
Net Income (TTM)
−$77.22M
+36.6% YoY
Q3 Sep 2023
EPS Diluted (TTM)
−$1.50
+61.8% YoY
Q3 Sep 2023
Gross Margin
—
Q3 Sep 2023
Operating Margin
—
Q3 Sep 2023
Net Margin
—
Q3 Sep 2023
Free Cash Flow (TTM)
−$100.95M
Q3 Sep 2023
Cash
$29.45M
Q3 Sep 2023
Total Debt
—
Q3 Sep 2023
Shares Outstanding
65.11M sh
Q3 Sep 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.